Obstructive Sleep Apnea Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, by DelveInsight | Takeda, Bayer, Apnimed, Desitin Arzneimittel GmbH, Eli Lilly, Jazz Pharma

The Obstructive Sleep Apnea Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Obstructive Sleep Apnea Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Obstructive Sleep Apnea Market.

Some of the key takeaways from the Obstructive Sleep Apnea Pipeline Report:

• Companies across the globe are diligently working toward developing novel Obstructive Sleep Apnea treatment therapies with a considerable amount of success over the years. 
• Obstructive Sleep Apnea companies working in the treatment market are Taisho Pharmaceutical Co., Ltd., Takeda, Bayer, Apnimed, Desitin Arzneimittel GmbH, Eli Lilly and Company, Axsome Therapeutics, Jazz Pharmaceuticals, Bioprojet Pharma, and others, are developing therapies for the Obstructive Sleep Apnea treatment 

• Emerging Obstructive Sleep Apnea therapies in the different phases of clinical trials are- TS-142, TAK-925, BAY 2586116, AD-109, Sulthiame, Tirzepatide, AD113, SUNOSI (Solriamfetol), OZAWADE (Pitolisant), and others are expected to have a significant impact on the Obstructive Sleep Apnea market in the coming years.   
• In January 2023, Pitolisant was the subject of a Phase III investigation by Aculys Pharma in Japan for the treatment of individuals with OSA and EDS
• In June 2022, A Master Protocol to Investigate the Efficacy and Safety of Tirzepatide Once Weekly in Participants Who Have Obstructive Sleep Apnea and Obesity: ARandomized, Double-Blind, Placebo-Controlled Trial' was started by Eli Lilly and Company
• In July 2022, In an announcement, Eli Lilly Japan K.K. and Mitsubishi Tanabe Pharma Corporation said they had inked a sales collaboration agreement in Japan for Tirzepatide, a drug that Eli Lilly Japan is currently developing

Obstructive Sleep Apnea Overview

The breathing disorder known as obstructive sleep apnea (OSA) occurs when the upper airway repeatedly becomes blocked while a person is asleep. When the upper airway is partially or completely blocked while a person is sleeping, they are said to have obstructed sleep apnea.

Get a Free Sample PDF Report to know more about Obstructive Sleep Apnea Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/obstructive-sleep-apnea-osa-pipeline-insight

Emerging Obstructive Sleep Apnea Drugs Under Different Phases of Clinical Development Include:

• TS-142: Taisho Pharmaceutical Co., Ltd.
• TAK-925: Takeda
• BAY 2586116: Bayer
• AD-109: Apnimed
• Lemborexant : Eisai
• Sulthiame : Desitin Arzneimittel GmbH
• AD 182 : Apnimed
• Sulthiame: Desitin Arzneimittel GmbH
• Tirzepatide: Eli Lilly and Company
• AD113: Apnimed
• SUNOSI (Solriamfetol): Axsome Therapeutics/Jazz Pharmaceuticals
• OZAWADE (Pitolisant): Bioprojet Pharma

Route of Administration

Obstructive Sleep Apnea pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types, such as

• Oligonucleotide
• Peptide
• Small molecule

Obstructive Sleep Apnea Pipeline Therapeutics Assessment

• Obstructive Sleep Apnea Assessment by Product Type
• Obstructive Sleep Apnea By Stage and Product Type
• Obstructive Sleep Apnea Assessment by Route of Administration
• Obstructive Sleep Apnea By Stage and Route of Administration
• Obstructive Sleep Apnea Assessment by Molecule Type
• Obstructive Sleep Apnea by Stage and Molecule Type

DelveInsight's Obstructive Sleep Apnea Report covers around 20+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Obstructive Sleep Apnea product details are provided in the report. Download the Obstructive Sleep Apnea pipeline report to learn more about the emerging Obstructive Sleep Apnea therapies

Some of the key companies in the Obstructive Sleep Apnea Therapeutics Market include:

Key companies developing therapies for Obstructive Sleep Apnea are - ResMed Inc., Philips Respironics, Fisher & Paykel Healthcare, SomnoMed, Inspire Medical Systems, Medtronic, BMC Medical Co., Ltd., Koninklijke Philips N.V., Itamar Medical, Weinmann Medical Technology, and others.

Obstructive Sleep Apnea Pipeline Analysis:

The Obstructive Sleep Apnea pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Obstructive Sleep Apnea with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Obstructive Sleep Apnea Treatment.
• Obstructive Sleep Apnea key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Obstructive Sleep Apnea Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Obstructive Sleep Apnea market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Obstructive Sleep Apnea drugs and therapies

Obstructive Sleep Apnea Pipeline Market Drivers

• Increase in prevalence of Obstructive Sleep Apnea (OSA), rising awareness of the disorder, are some of the important factors that are fueling the Obstructive Sleep Apnea Market.

Obstructive Sleep Apnea Pipeline Market Barriers

• However, lack of approved drugs, complexity of OSA pathogenesis.and other factors are creating obstacles in the Obstructive Sleep Apnea Market growth.

Scope of Obstructive Sleep Apnea Pipeline Drug Insight    

• Coverage: Global
• Key Obstructive Sleep Apnea Companies: Taisho Pharmaceutical Co., Ltd., Takeda, Bayer, Apnimed, Desitin Arzneimittel GmbH, Eli Lilly and Company, Axsome Therapeutics, Jazz Pharmaceuticals, Bioprojet Pharma, and others
• Key Obstructive Sleep Apnea Therapies: TS-142, TAK-925, BAY 2586116, AD-109, Sulthiame, Tirzepatide, AD113, SUNOSI (Solriamfetol), OZAWADE (Pitolisant), and others
• Obstructive Sleep Apnea Therapeutic Assessment: Obstructive Sleep Apnea current marketed and Obstructive Sleep Apnea emerging therapies
• Obstructive Sleep Apnea Market Dynamics: Obstructive Sleep Apnea market drivers and Obstructive Sleep Apnea market barriers 

Request for Sample PDF Report for Obstructive Sleep Apnea Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services